Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis

IMPORTANCE: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal adenomas and cancer. Combination sulindac and erlotinib was previously shown to reduce duodenal polyp burden but was associated with a relatively high adverse event (AE) rate. Objective: To eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Samadder, N Jewel, Foster, Nathan, McMurray, Ryan P, Burke, Carol A, Stoffel, Elena, Kanth, Priyanka, Das, Rohit, Cruz-Correa, Marcia, Vilar, E, Mankaney, Gautam, Buttar, Navtej, Thirumurthi, Selvi, Turgeon, Danielle K, Sossenheimer, Michael, Westover, Michelle, Richmond, Ellen, Umar, Asad, Della'Zanna, Gary, Rodriguez, Luz M, Szabo, Eva, Zahrieh, David, Limburg, Paul J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
GI cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708943/
https://www.ncbi.nlm.nih.gov/pubmed/35636921
http://dx.doi.org/10.1136/gutjnl-2021-326532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708943/
https://www.ncbi.nlm.nih.gov/pubmed/35636921
http://dx.doi.org/10.1136/gutjnl-2021-326532

Ejemplares similares